Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39177889/
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite the availability of numerous disease-modifying...
This review explores current and emerging therapies for multiple sclerosis, focusing on novel targets like monoclonal antibodies, CAR T cell therapy, microglia, ferroptosis, and microbiota-based interventions for holistic management.
Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38529035/
https://inplasy.com/?s=202320071, identifier: 202320071.
This systematic review evaluates the efficacy and safety of disease-modifying therapies for progressive multiple sclerosis, finding mitoxantrone, siponimod, and ocrelizumab most effective in delaying progression and mitigating disability.
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39379875/
Limitations of these analyses included the potential for confounding due to pseudoatrophy, and a lack of long-term clinical data for BVL. Our findings suggest that important differences in BVL may...
This study reviewed randomized trials on disease-modifying therapies (DMTs) in relapsing multiple sclerosis (RMS), highlighting significant differences in brain volume loss (BVL) reduction, emphasizing the need for further BVL-focused research.
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39749348/
The immunogenicity profile of biosim-NTZ was confirmed to match that of ref-NTZ in healthy subjects and patients with RRMS by applying highly sensitive methods.
Biosimilar natalizumab demonstrated matching immunogenicity to reference natalizumab in RRMS patients and healthy subjects, with similar ADA/NAb incidence and titers, confirming biosimilarity using highly sensitive bioanalytical assays.
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39393045/
ClinicalTrials.gov, NCT03689972; EudraCT, 2018-002145-11. Submitted 2018-09-27. First patient enrolled: 2018-12-26. https://clinicaltrials.gov/study/NCT03689972.
Extended-interval natalizumab dosing (Q6W) reduced PML risk while maintaining efficacy in most RRMS patients. Q6W decreased trough drug levels and α4-integrin saturation but did not consistently predict lesion or relapse activity.